Q-omics provides the consensus-scored NDN profile across patient tissues and cancer cell-line models. NDN expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, NDN is differentially expressed in 15, with the highest sampling consensus in KICH. Additionally, NDN RNA expression shows 18,645 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight UVM, KICH, and BRCA as cancer lineages where NDN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NDN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NDN survival associations across molecular data types. NDN RNA expression shows survival associations in the most cancer types (21), followed by mutation status (11) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NDN RNA expression–survival associations across cancer types. High NDN expression shows unfavorable associations in SKCM, but favorable associations in UVM, UCEC, LGG, OV and THCA. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for NDN RNA expression.
This table summarizes NDN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in LUAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for NDN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NDN shows lower tumor expression in KICH, COAD, LUAD, UCEC, BLCA and LUSC. The KICH box plot shows higher NDN RNA expression in normal versus tumor tissue (log2 FC = −3.195, t-test p < 0.001).
This table shows molecular features associated with NDN in patient tissues and cancer cell lines. In patient samples, NDN shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, NDN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
